Equillium (EQ) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability
2. 02failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment
3. 03the cost associated with commercializing our product candidates if any are approved for commercial sale
4. 04Our corporate cash saving initiatives and the associated headcount reductions we implemented, and potential additional headcount reductions in the future, could disrupt our business, and may not achieve our intended objectives

Risks Related to our Business and to the Development and Regulatory Approval of our Product Candidates

1. 05revenues from sales of any biopharmaceutical products, and we may never be able to develop or commercialize a marketable biopharmaceutical product
2. 06We have and may in the future enter into partnerships or similar arrangements or otherwise monetize our pipeline through strategic transactions, which may harm our ability to realize a return, if any, on our investments and may increase our need for external funding
3. 07We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations with respect to our current or future product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans
4. 08industry and market conditions generally
5. 09We have limited experience in clinical development and have not successfully completed late-stage clinical studies or obtained regulatory approval of any product candidate
6. 10If we do not achieve one or more of these factors in a timely manner, we could experience significant delays or an inability to successfully obtain marketing approval and commercialize our product candidates, which would materially harm our business
7. 11If we fail to develop or acquire other product candidates or products, our business and prospects would be limited
8. 12Potential natural disasters, some possibly related to the increasing effects of climate change, could damage, destroy or disrupt clinical study sites, our office spaces, laboratories, and/or warehouses, which could have a significant negative impact on our operations
9. 13The development and commercialization of biopharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals of our product candidates in any of the indications for which we plan to develop them, or any future product candidates, on a timely basis or at all
10. 14may not accept a submission due to, among other reasons, the content or formatting of the submission
11. 15Any delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical studies could result in increased costs to us, delay or limit our ability to raise capital or generate revenue and adversely affect our commercial prospects
12. 16If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical studies, or if we decide to enroll fewer subjects than the study protocol specifies for business reasons, our receipt of necessary regulatory approval could be delayed or prevented
13. 17impacts and risks associated with global health epidemics or outbreaks
14. 18Based on our current limited clinical experience with itolizumab (EQ001), expected adverse events include lymphopenia, injection site reactions, infusion-/injection-related reactions (including fever and headache), and other systemic hypersensitivity reactions including rash, urticaria, erythema, and pruritus
15. 19market acceptance of our product candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly
16. 20Interim, topline or preliminary data from our clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
17. 21differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock
18. 22diminished protection of intellectual property in some countries
19. 23FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed
20. 24Even if our product candidates receive marketing approval in any indication, they may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success
21. 25the prevalence and severity of any side effects
22. 26We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated
23. 27Our current product candidates and any future product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
24. 28If market opportunities for our product candidates are smaller than we believe they are, our potential revenue may be adversely affected and our business may suffer
25. 29We may not ultimately realize the potential benefits of orphan drug designation for itolizumab (EQ001) or, if we resume development activities, EQ101
26. 30Fast-track designation by the FDA may not actually lead to a faster development or regulatory review or approval process
27. 31Even if we receive marketing approval, we may not be able to successfully commercialize any of our approved products due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell any of our approved products profitably
28. 32neither experimental nor investigational
29. 33we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition

Risks Related to Manufacturing and Our Reliance on Third Parties

1. 34Our reliance on contracted parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Intellectual Property

1. 35We depend on intellectual property licensed from Biocon and termination of our license could result in the loss of significant rights, which would harm our business
2. 36the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners
3. 37In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated
4. 38Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
5. 39We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
6. 40If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
7. 41We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
8. 42Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
9. 43We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
10. 44We may not be able to protect our intellectual property rights throughout the world
11. 45Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 46We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
13. 47and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets
14. 48We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
15. 49Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
16. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
17. 51Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Employees, Managing Our Growth and Other Legal Matters

1. 52We are highly dependent on the services of our key personnel
2. 53improve our operational, financial and management controls, reporting systems and procedures
3. 54Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel
4. 55Third-party expectations relating to environmental, social and governance factors may impose additional costs and expose us to new risks
5. 56Our employees, clinical study investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
6. 57circumstances, we could be subject to penalties, including criminal penalties, if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA
7. 58States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws
8. 59Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
9. 60We conduct significant operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer
10. 61If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and prospects may be materially and adversely affected
11. 62authorizing activities relating to the commercialization of itolizumab (EQ001), or the Submission. We simultaneously requested that OFAC treat the Submission as a voluntary disclosure if OFAC concluded that our determination that the general license applies to itolizumab (EQ001) was in error
12. 63Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations
13. 64The Affordable Care Act substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry
14. 65If any of our services providers are characterized as employees, we would be subject to employment and tax withholding liabilities and other additional costs
15. 66We may be subject to applicable foreign, federal and state fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties

Risks Related to Ownership of our Common Stock

1. 67The stock price of our common stock may be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment
2. 68any other factors discussed in this report
3. 69Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
4. 70Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends
5. 71If there are substantial sales of shares of our common stock, the price of our common stock could decline
6. 72Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for other stockholders to sell shares of our common stock
7. 73The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval
8. 74Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
9. 75Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims
10. 76any action asserting a claim against us that is governed by the internal-affairs doctrine
11. 77As a public company in the United States, we incur significant legal and financial compliance costs and we are subject to the Sarbanes-Oxley Act. We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective
12. 78Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
13. 79Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any product candidates that we may develop
14. 80the inability to commercialize any products that we may develop
15. 81Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
16. 82We are subject to risks related to taxation in multiple jurisdictions
17. 83If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
18. 84If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
19. 85Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
20. 86We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met
21. 87We are a “smaller reporting company” and a “non-accelerated filer” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to smaller reporting companies or non-accelerated filers could make our common stock less attractive to investors
22. 88We do not intend to pay dividends for the foreseeable future
23. 89We could be subject to securities class action litigation